SynapDx Corp., a Lexington company currently developing diagnostics for the earlier detection of autism, said it has formed an alliance with Illumina Inc., a California company that specializes in life sciences tools.
A goal of the alliance is to combine SynapDx’s proprietary autism technologies with Illumina’s sequencing platform to develop early detection tools for autism spectrum disorders, the companies said.
In addition, the companies plan to leverage their joint expertise to broadly evaluate other opportunities in neurodevelopment, SynapDx and Illumina said in a press release.
“SynapDx and Illumina share a vision of better pediatric care through the use of advanced molecular assays and sequencing technologies,” Stanley Lapidus, SynapDx’s chief executive, said in a statement. “We look forward to broadly collaborating on multiple joint initiatives.”